KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Working Capital Changes (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Other Working Capital Changes data on record, last reported at -$272000.0 in Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 120.83% year-over-year to -$272000.0; the TTM value through Dec 2025 reached -$571000.0, down 356.05%, while the annual FY2025 figure was -$571000.0, 356.05% down from the prior year.
  • Other Working Capital Changes reached -$272000.0 in Q4 2025 per AQST's latest filing, roughly flat from -$273000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $7.6 million in Q1 2022 and bottomed at -$11.9 million in Q4 2022.
  • Average Other Working Capital Changes over 5 years is -$214750.0, with a median of $215000.0 recorded in 2023.
  • The widest YoY moves for Other Working Capital Changes: up 1320.93% in 2022, down 2325.79% in 2022.
  • A 5-year view of Other Working Capital Changes shows it stood at $535000.0 in 2021, then plummeted by 2325.79% to -$11.9 million in 2022, then soared by 68.68% to -$3.7 million in 2023, then soared by 135.02% to $1.3 million in 2024, then tumbled by 120.83% to -$272000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were -$272000.0 in Q4 2025, -$273000.0 in Q3 2025, and $235000.0 in Q2 2025.